IP Library › Granted Patent US 8,420,591
Granted Patent B2
US 8,420,591 · App. 12/517,762 · Granted Apr 16, 2013

MUC1 and galectin-3

Inventor: Donald W. Kufe (Wellesley, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,420,591
App. No.
12/517,762
Granted
Apr 16, 2013
Kind
B2
Abstract

The invention provides methods of identifying and making compounds that inhibit the interaction between MUC1 and galectin-3. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of galectin-3 by a cell.

Claims (3)

1. A method of inhibiting binding of MUC1-C to galectin-3 in a cancer cell that expresses MUC1-C, the method comprising:

contacting the cancer cell with a peptide fragment that comprises the extracellular domain, of MUC1-C, wherein said peptide fragment inhibits binding of galectin-3 to the extracellular domain of MUC1-C.

2. The method of claim 1 , wherein the peptide fragment is fused to an immunoglobulin Fc region.

Assignments (2)
CONFIRMATORY LICENSE Recorded Sep 2, 2015
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036528/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2009
From: KUFE, DONALD W.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 023078/0058 →
Continuity (2)
Provisional Application 60873847 · Dec 8, 2006
Related Publication 20100098683A1 · Apr 22, 2010